The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC

Bladder Cancer MORE >>

Patients with metastatic renal and urothelial bladder cancer who receive antibiotics concomitantly with immune checkpoint inhibitors have shorter progression-free survival and overall survival rates than patients who do not, according to a poster presented at the European Congress on Immunotherapies in Cancer™ conference, hosted by Physicians’ Education Resource®, LLC, September 21 and 22, 2018, in Barcelona, Spain.

Latest JournalAll Journals >>

Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.